Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actinogen Medical ( (AU:ACW) ) has provided an update.
Actinogen Medical has dispatched four senior executives to San Francisco to meet investors, analysts and potential partners at the Sachs Neuroscience Innovation Forum and events around the J.P. Morgan Healthcare Conference, aiming to raise the company’s profile among key neuroscience-focused stakeholders. The meetings centre on the company’s Xanamem Alzheimer’s program, highlighting multiple supportive clinical trials and the advanced XanaMIA Phase 2b/3 study, which has completed recruitment and is on track to deliver an interim analysis in late January 2026 and final topline results in November 2026, a timeline that could be pivotal for Actinogen’s clinical and commercial positioning if the data are positive.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Its lead candidate, Xanamem, a once-daily oral 11β-HSD1 inhibitor, is being advanced primarily as a treatment for Alzheimer’s disease, with prior clinical work in depression and potential future applications in other conditions such as Fragile X syndrome, targeting substantial unmet medical needs in cognitive and mood disorders.
YTD Price Performance: -3.28%
Average Trading Volume: 5,003,163
Technical Sentiment Signal: Buy
Current Market Cap: A$188.3M
See more insights into ACW stock on TipRanks’ Stock Analysis page.